CRIS | tickerfilter.com

Fundamental analysis

32%

Profitability 25%

Dept financing 23%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-12.78%

1 Month

-58.42%

3 Months

-66.47%

6 Months

-76.85%

1 Year

-92.97%

2 Year

-91.06%

Key data

Stock price

$1.16

P/E Ratio

0.00

DAY RANGE

$1.10 - $1.22

EPS

-$5.95

52 WEEK RANGE

$1.10 - $16.99

52 WEEK CHANGE

-$92.55

MARKET CAP

32.227 M

YIELD

N/A

SHARES OUTSTANDING

5.979 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

1.61

PUBLIC FLOAT

AVERAGE 10 VOLUME

$136,294

AVERAGE 30 VOLUME

$67,250

Company detail

CEO: James E. Dentzer
Region: US
Website: curis.com
Employees: 60
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial. CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

CRIS - CURIS INC